Key points highlighted in the session included: GLP-1 receptor agonists have been used clinically since 2005, with earlier formulations prescribed at lower doses Newer medications and dosing regimens have increased weight loss outcomes Public familiarity with medications such as Ozempic, Wegovy, Mounjaro, and Zepbound has grown rapidly Increased access and demand have led to broader prescribing patterns and new clinical questions This growth has outpaced many clinicians training around eating disorder risk and weight-inclusive care
has served on scientific advisory panels and/or speaker's bureaus and served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Novo Nordisk, Sanofi and Zealand Pharma
Once reconstituted in sterile aqueous vehicle, the solution should be maintained at 4 C and used within 5 to 7 days
4/ Leadership Transition and Strategic Direction Novo Nordisks leadership change raised questions, though not all concern is warranted
.png)
